Background: Warfarin is the oral anticoagulant that is most commonly used to control and prevent thromboembolic disorders. It requires meticulous testing and dosing adjustments to attain therapeutic international normalized ratio (INR) levels. Patient selftesting (PST) is associated with a reduced risk of all-cause mortality and lower rates of thromboembolism and bleeding. PST meters offers convenience and promotes selfinitiative of care.
Background & Evidence for problem
Warfarin is the oral anticoagulant that is most commonly used to control and prevent thromboembolic disorders. According to the Joint Commission improper monitoring of anticoagulants resulted in loss of function and deaths in 26% of the nation.
Warfarin is a medication that requires meticulous testing and dosing adjustments to attain therapeutic International Normalized Ration (INR) levels. An INR level is a crucial laboratory measurement to make certain the blood will not put the patient at risk for bleeding or clotting. The goal of warfarin management is to administer a therapeutic dose to provide the patient protection against clotting conditions and minimizing the risk of bleeding. Signs of warfarin overtreatment are increased bruising, excessive bleeding, and presence of blood in stool and emesis. The increase danger of bleeding further complicates safety awareness in older patients. Under treatment may increase the risk for blood clots, which may dislodge into small arteries in the brain or heart causing stroke or myocardial infarction. Challenges of usual laboratory testing are time and scheduling inconveniences, separate visits for blood draw and result interpretation, possible return to the lab for system error, therefore possible delay in treatment, multiple medical consultations, and lack of independence.
The main challenge observed in this cardiology practice has been an increase of patients on warfarin who have acquired complications from non-therapeutic INR's and required immediate intervention including hospitalization.
Evidence-based intervention
The intended population in this a cardiology clinic are adults who are currently receiving warfarin management. The utilization of patient-self testing (PST) is the planned intervention to maintain a therapeutic INR. Evidence discussed has shown PST is just as accurate as conventional laboratory methods (Garcia-Alamino et al., 2012) . The PST is a portable device allowing convenience of INR testing in the comfort of the patients' own home. The meter is very similar to glucometers used for diabetic patients.
A sample of blood is collected from a fingerstick using a lancet. The test strip is inserted into the pocket-sized device and blood is dropped on to the strip. The result is available immediately. The device works by measuring thromboplastin-mediated clotting time, then converted to plasma PT and expressed as an INR value. The health care provider will receive the INR reports from the meter vendor providing PST service as results become available.
PST would allow for more frequent monitoring, better treatment adherence, and fewer thromboembolic or hemorrhagic complications (Heneghan, 2012 ). An estimated 19,380 strokes and 916 bleeds would be prevented each year by home INR testing (Caro, 2004) . "A conservative economic model estimated a Medicare savings of $1.14 billion annually through maintaining patients eligible for anticoagulation on therapeutic doses of warfarin" (Caro, 2004) .
Evidence of Accuracy in Patient Care Settings
There is strong evidence that PST meters are just as accurate as laboratory findings and are effective to utilize in practice. In a systematic review by Christensen & Larsen (2012) (1980 ( -2009 ( ) and MEDLINE (1966 ( -2009 . The review indicated a 55% reduction in thromboembolic events, 35% reduction in bleeding, and a 39% reduction in all-cause mortality (Heneghan, Ward, Perera, & the Self-monitoring Trial Collaboration, 2012).
Heneghan et al. also found improvements on INR measurements within therapeutic range
in patients that were self-monitoring.
Implementation
The purpose of the project is to evaluate the effectiveness of INR PST in adult patients diagnosed with atrial fibrillation, deep vein thrombosis, and mechanical heart valve on warfarin therapy in a Cardiology practice compared to traditional laboratory methods, or usual care. The selection of patients to participate in this study was provided by the practice and gathered by a computer generated list using the ICD-9 code for patients on anticoagulant therapy. Data were obtained from two groups of patients on oral warfarin: 1) patients testing INR's levels via usual care and 2) patients currently utilizing PST meters. The practice had 13 patients on PST meters. Inclusion criteria include warfarin therapy for six months or longer, diagnosis of atrial fibrillation, mechanical heart valve, and/or history of deep vein thrombosis. All data were obtained from medical records. Data obtained from the patients' medical records, over a four-year time period Patients in the usual care group had unpredictable and varying INR values. There were no specific patterns observed. INR's were tested at least monthly. These patients were in therapeutic range approximately 50% of the time.
Cost Implications
There were no extra costs spent by the practice prior to implementation. Medicare remains the top insurer for adults in this population. Fortunately, Medicare covers PST meters for patients, reimburses the practice for the initial PST education prior to implementation as well as use of PST monitoring monthly (Bloomfield, 2011) . This study revealed tighter control in the PST group after initiation of meters. There was an undesirable trend observed through data collection after the three-month initiation period, which suggests need for follow-up intervention.
Implications for Clinical Practice and Sustainability
PST INR testing method is easily sustainable in this practice setting. Appropriate provider follow-up and support are the foundations of successful patient outcomes for patient self-testing. This study suggests a three month follow-up visit may be needed to reinforce testing frequency and compliance. During this visit it is crucial to identify and correct any possible barriers to testing.
Discussion
New anticoagulants have recently been introduced as an alternative to warfarin.
These medications do not require close monitoring with INR testing, provide convenience of standard dosing, and have fewer bleeding and stroke risks (Buller et al., 2013) . Examples of these medications are clopidogrel, ticagrelor, rivaroxaban, and edoxaban.
The Rocket AF trial compared effectiveness of rivaroxaban and warfarin to prevent stroke or systemic embolism in patients with nonvalvular atrial fibrillation.
Rivaroxaban proved less frequent intracranial and fatal bleeding than warfarin and appeared to match effectiveness of warfarin in prevention of stroke and embolism (P< 0.001). Edoxaban is a newer anticoagulant in the same pharmaceutical category. It is primarily given to prevent venous thromboembolism. In a study by Buller et al., Edoxaban resulted in 3.3% rate of recurrent venous thromboembolism while warfarin resulted in 6.2% recurrence rate.
The PLATO study compared ticagrelor to clopidogrel to determine superiority on prevention of vascular events and death in patients with an acute coronary syndrome.
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